Match Document Document Title
7585849 Position dependent recognition of GNN nucleotide triplets by zinc fingers  
The specificity of binding of a zinc finger to a triplet or quadruplet nucleotide target subsite depends upon the location of the zinc finger in a multifinger protein and, hence, upon the location...
7585675 Inhibition of HIV and SHIV replication with antisense interleukin-4  
A method of treating or preventing SHIV or HIV infection in a subject comprising administering a therapeutically effective amount of a antisense IL-4. The antisense IL-4 inhibits viral replication...
7585969 MicroRNA and methods for inhibiting same  
The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to...
7585967 Nucleic acid compounds for inhibiting angiogenesis and tumor growth  
In certain embodiments, this present disclosure provides nucleic acid compounds, compositions, and methods for inhibiting Ephrin B2 or EphB4 expression. In certain embodiments, the present...
7585847 Immunostimulatory nucleic acids for the treatment of asthma and allergy  
The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in...
7585848 Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc  
Described herein are methods and compositions for inhibiting, treating and reversing intervertebral disc disorders using transcription factor inhibitors. In certain embodiments, the transcription...
7585497 Induction of apoptosis and cell growth inhibition by protein 4.33  
There is disclosed an isolated cDNA sequence (SEQ ID NO:1) encoding a P4.33 polypeptide and comprising a coding region (SEQ ID NO:2) of the sequence described in SEQ ID NO:1, or a sequence having...
7582614 Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection  
The present invention relates to therapeutic use of Myxoma virus. Myxoma virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive...
7582744 Chemically modified oligonucleotides  
This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.
7582619 Compositions and methods for treatment of mitochondrial diseases  
Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidine...
7582613 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines  
The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of...
7582747 siRNA targeting inner centromere protein antigens (INCENP)  
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
7582289 Viruses for the treatment of cellular proliferative disorders  
Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately...
7582618 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections  
The 3′-L-valine ester of β-D-2′-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery,...
7582746 siRNA targeting complement component 3 (C3)  
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
7582615 Antisense antiviral compound and method for treating arenavirus infection  
The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Arenaviridae family and in the treatment of a viral infection....
7582745 Compositions and methods for inhibiting expression of Nav1.8 gene  
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which...
7579458 siRNA targeting synuclein, alpha (SNCA-1)  
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
7579328 DNA vaccination for treatment of multiple sclerosis and insulin-dependent diabetes mellitus  
A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further...
7579326 Gene switch systems employing regulators with decreased dimerization  
Disclosed is a novel inducible expression system characterized by undetectable biological effect in the absence of an inducer, but which exhibits efficient inducibility in the presence of an inducer.
7579330 Methods of treating various cancers using melanoma differentiation associated protein-7  
This invention provides a method for reversing the cancerous phenotype of a cancer cell by introducing a nucleic acid having the melanoma differentiation associated gene (mda-7) into the cell under...
7579457 siRNA targeting carbonic anhydrase II  
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene...
7579318 Cell penetrating peptides for intracellular delivery of molecules  
The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX 9 WRAX 9 WRX 1 LX 2 RSLX 9 WX 3 X 4 X 5 X 6 X 7 X 8 (SEQ ID No: 1), wherein X 1 is...
7579327 Promoters exhibiting endothelial cell specificity and methods of using same  
An isolated polynucleotide functional as a promoter in eukaryotic cells is disclosed. The isolated polynucleotide includes an endothelial specific enhancer element as detailed herein. Further...
7579455 Oligonucleotide compositions and methods for treating disease including inflammatory conditions  
The invention relates to therapeutic antisense oligonucleotides directed against genes coding for phosphodiesterase (PDEs) and the use of these in combination. These antisense oligonucleotides may...
7579452 Cancer vaccine based on brother of regulator of imprinted sites molecule  
Polynucleotides encoding a nonfunctional mutant form of the Brother of Regulator of Imprinted Sites (BORIS) molecule, nonfunctional mutated BORIS protein, polypeptide or peptide and modified...
7579329 P450RAI-2 (P450 cytochrome 26B), encoding nucleic acid molecules and methods and uses thereof  
The present invention provides a novel all-trans-RA inducible all-trans-RA metabolizing cytochrome P450, P450RAI-2, that is predominantly expressed in the brain, cerebellum in particular. It is...
7576066 Nucleic acid compositions for stimulating immune responses  
The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.
7575743 Compositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells  
Compositions and methods are provided for treatment of cartilage defects in animals and humans. The compositions of the invention include synovial tissue, synovial cells and matrices containing...
7576197 SiRNA targeting KRAS  
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs directed to silencing KRAS, one can maximize the generation of an...
7576196 siRNA targeting transducin (beta)-like 3 (TBL3)  
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
7576065 Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein  
The present invention relates to a method of inducing neuronal production in a subject, a method of recruiting neurons to a subject's brain, and a method of treating a neurodegenerative condition...
7576067 Pulsatile release compositions and methods for enhanced intestinal oligonucleotide drug absorption  
Delayed release oral pharmaceutical formulations and methods for enhanced intestinal drug absorption. The formulation comprises a first population of carrier particles comprising a drug and a...
7575918 Tissue-specific and pathogen-specific ribozymes  
The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or...
7572628 Eukaryotic layered vector initiation systems  
The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector...
7572633 Use of the adenoviral E2 late promoter  
The invention relates to a nucleic acid construct comprising an adenoviral E2 late promoter or a fragment thereof and a nucleic acid. The nucleic acid is selected from the group of transgenes,...
7572434 Method for assessing the effect of a drug on long term memory formation  
Methods of assessing the effect of a drug on long term memory and for screening a pharmaceutical agent for its ability to modulate long term memory are disclosed.
7572438 Mutant having uracil phosphoribosyl transferase activity  
The invention concerns a polypeptide having a uracil phosphoribosyl transferase (UPRTase) by mutation of one or several residues of the UPRTase. The invention also concerns a nucleotide sequence...
7569554 Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents  
The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
7569684 siRNA targeting gremlin  
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
7569552 DNA vaccines against tumor growth and methods of use therof  
A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1...
7569553 Nucleic acid compositions for stimulating immune responses  
The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.
7569659 Admixture comprising a target molecule and a nucleic acid mimic comprising sterically bulky substituents  
The invention concerns compositions comprising a nucleic acid mimic. The compositions may be used in the diagnosis and treatment of diseases amenable through modulation of nucleic acids which...
7569551 Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides  
Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells...
7566700 Materials and methods for treatment of allergic disease  
siRNA molecules are disclosed which target the transcription factor STAT6 and repress the expression of STAT6 mRNA, STAT6 protein and STAT6 function in lung cells. The use of STAT6 specific siRNA...
7566701 Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics  
The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic...
7566703 Semi-soft C-class immunostimulatory oligonucleotides  
The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for...
7566702 Immunostimulatory oligonucleotide multimers  
The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is...
7566454 Influenza nucleic acids, polypeptides, and uses thereof  
Codon-optimized nucleic acids encoding influenza polypeptides and uses of the nucleic acids and polypeptides for inducing immune responses are provided herein.
7563778 Antisense oligonucleotide preparation method  
A method for the preparation of an antisense oligonucleotide or derivative thereof comprising the steps of: selecting a target nucleic acid, if necessary elucidating its sequence; generating the...